Toripalimab and JS004 for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs, toripalimab and JS004, for patients with advanced kidney cancer that has returned or spread. It aims to see if this therapy can help when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced kidney cancer that came back or spread after surgery.
- You have tried one type of systemic therapy (like targeted or immunotherapy) and it stopped working or caused side effects.
- You must have at least one tumor that can be measured on scans.
- You need to be in good enough health to walk and take care of yourself (ECOG score 0 or 1).
- You must provide a tissue sample from a past surgery for testing.
- You cannot have certain other cancers, active autoimmune diseases, or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests an investigational medicine called HS-IT101 for people with advanced kidney cancer that hasn't responded to standard treatments. The goal is to see if this new therapy can help shrink or control the cancer.
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
This trial tests a new drug (JS004) combined with an existing immunotherapy (toripalimab) for kidney cancer that has progressed after previous immunotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs — an immunotherapy (toripalimab) and a targeted therapy (axitinib) — as the first treatment for advanced kidney cancer. The approach may shrink the tumor before deciding whether and when to remove the kidney surgically.
This trial tests a combination of two drugs—an immunotherapy called toripalimab and a targeted therapy called axitinib—for people with rare kidney cancers that have spread. The goal is to see if this combination can shrink or control the cancer before any surgery to remove the kidney.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.